Introduction
Distinguishing between benign and malignant bile duct strictures remains one of the most persistent challenges in gastroenterology and hepatobiliary oncology. Current diagnostic approaches relying on endoscopic retrograde cholangiopancreatography (ERCP)-guided tissue sampling have long been plagued by suboptimal sensitivity, particularly in challenging populations such as patients with primary sclerosing cholangitis (PSC). A groundbreaking six-year prospective study published in Gastroenterology now demonstrates that DNA/RNA-based next-generation sequencing (NGS) can substantially improve both early detection and clinical management of neoplastic bile duct strictures.
Background: The Diagnostic Dilemma
Bile duct strictures represent a heterogeneous group of conditions ranging from benign inflammatory processes to aggressive malignancies such as cholangiocarcinoma and pancreatic ductal adenocarcinoma. The clinical stakes are exceptionally high—missing a malignancy can result in delayed treatment and worse survival outcomes, while overcalling cancer leads to unnecessary surgeries and patient anxiety.
Traditional diagnostic methods face significant limitations. Endoscopic brush cytology and forceps biopsy obtained during ERCP provide tissue for pathological examination, but their sensitivity for detecting malignancy remains disappointingly low. This limitation is particularly pronounced in PSC patients, who face inherently elevated cancer risk yet develop strictures that are notoriously difficult to characterize due to underlying inflammation and fibrosis. These patients often require multiple invasive procedures and extended surveillance before a definitive diagnosis can be established.
Molecular diagnostics have emerged as a promising adjunct to conventional pathology. By detecting genetic alterations associated with malignancy—including mutations, fusions, and copy number variations—NGS testing can identify neoplastic processes that might be missed on morphological examination alone. However, prior studies have been limited by single-institution designs, small sample sizes, or incomplete genomic profiling.
Study Design
The current investigation represents the most comprehensive prospective evaluation of molecular testing for bile duct strictures to date. Conducted across 28 medical institutions over six years, the study enrolled 2,116 patients who underwent ERCP with collection of brushings, biopsies, and/or bile specimens. A total of 2,908 specimens were analyzed.
Two generations of the BiliSeq assay were employed during the study period. BiliSeqV2, utilized in earlier phases, interrogated 28 cancer-associated genes and 167 fusion genes. BiliSeqV3, the more comprehensive version, expanded coverage to 161 cancer-associated genes and 763 fusion genes. Molecular results were correlated with clinical parameters, imaging studies, and pathological assessments. Diagnostic reference standard consisted of definitive pathological diagnosis and/or clinical follow-up for at least one year.
Of the 2,865 specimens (99%) successfully analyzed with BiliSeqV2/V3 from 2,080 patients (98%), follow-up data was available for 1,979 patients (95%). The study population included substantial representation of high-risk subgroups, including Hispanic patients, germline mutation carriers, and individuals with underlying PSC.
Key Findings
The primary results demonstrate a substantial improvement in diagnostic performance with molecular testing compared to pathology alone. BiliSeqV2/V3 achieved 82% sensitivity for neoplastic strictures, with 98% specificity. In stark contrast, pathological assessment alone yielded only 44% sensitivity while maintaining 99% specificity. When the two approaches were combined, sensitivity further improved to 88% with preserved specificity of 97%.
The performance differential was even more dramatic in high-risk populations where traditional methods historically struggle. Among Hispanic patients, germline mutation carriers, and PSC patients, BiliSeqV2/V3 demonstrated sensitivity ranging from 74% to 86%, compared to pathological assessment sensitivity of only 26% to 50% in these same groups.
Beyond diagnostic accuracy, the study examined the clinical utility of molecular findings. Actionable molecular alterations—genomic changes with potential therapeutic implications—were identified in 20% of neoplasms that tested positive on BiliSeqV3. Critically, these molecular findings directly modified patient management in 30% of cases where alterations were detected, demonstrating that NGS testing provides not only diagnostic but also therapeutic decision-making value.
The comprehensive gene panels proved advantageous. The expanded coverage of BiliSeqV3 enabled detection of a broader spectrum of alterations, improving both sensitivity and the yield of clinically relevant molecular information compared to earlier iterations of the assay.
Clinical Implications
These findings carry significant implications for clinical practice in gastroenterology and hepatobiliary oncology. The near-doubling of sensitivity achieved by NGS testing means that fewer malignancies would be missed on initial ERCP evaluation. For patients with indeterminate strictures, molecular profiling can provide additional diagnostic confidence that may guide decisions regarding surgical intervention, surveillance intervals, or conservative management.
The particularly impressive performance in PSC patients addresses a long-standing unmet need. This population requires vigilant surveillance for biliary malignancy, yet current monitoring strategies are confounded by the baseline inflammatory changes that characterize PSC. The ability to achieve 74-86% sensitivity in this challenging group could transform surveillance protocols and reduce the need for repeated invasive procedures.
The identification of actionable alterations in one-fifth of neoplasms represents a paradigm shift toward precision oncology in biliary disease. Previously, molecular profiling was primarily considered in the metastatic setting. These data suggest that comprehensive genomic analysis should be incorporated earlier in the diagnostic algorithm, potentially informing neoadjuvant treatment planning or eligibility for targeted therapy trials.
Limitations and Considerations
Several limitations merit acknowledgment. The study was conducted at academic medical centers with expertise in advanced endoscopy and molecular diagnostics, which may limit generalizability to community practice settings. The one-year follow-up period, while clinically meaningful, may not capture all slowly progressive malignancies. Additionally, the therapeutic impact data—30% management modification—reflects clinician-reported changes and would benefit from validation in prospective intervention studies.
Implementation challenges include the need for specialized laboratory infrastructure, expertise in genomic data interpretation, and integration of molecular results with clinical decision-making. Reimbursement and turnaround time remain practical barriers to widespread adoption.
Conclusion
This landmark prospective study establishes DNA/RNA-based NGS testing as a transformative tool for the evaluation of bile duct strictures. By achieving 82% sensitivity—nearly double that of conventional pathology—while maintaining 98% specificity, molecular profiling addresses the fundamental diagnostic limitation that has challenged clinicians for decades. The particularly strong performance in historically difficult populations such as PSC patients, combined with the substantial rate of actionable findings that altered management, positions NGS testing as an essential component of modern biliary disease evaluation. As molecular diagnostics continue to evolve and integrate into routine practice, the early detection of bile duct malignancies—and the precision targeting of their molecular drivers—will increasingly become clinical reality.